BPC-157: What the Research Actually Shows

The short answer

BPC-157 is a synthetic 15-amino-acid peptide sequence derived from a protein found in gastric juice. Almost the entire published literature on it is preclinical — overwhelmingly rodent work, much of it from a single research group — and there are essentially no completed, published randomised controlled trials in humans. It holds no medicines approval in the United Kingdom, the United States or the European Union, and it has been named on the World Anti-Doping Agency Prohibited List since 2022.

What the compound is

BPC-157 is described in the literature as a pentadecapeptide: a chain of fifteen amino acids. The sequence was identified as a fragment of a larger protein, body protection compound, isolated from human gastric juice. The material sold and used in laboratories is produced synthetically rather than extracted, and is typically supplied as a lyophilised powder, sometimes as an acetate or arginate salt. The distinction between salt forms matters to researchers because stability characteristics differ, and much of the published animal work does not clearly specify which form was used.

The shape of the evidence base

This is the single most important thing to understand about BPC-157, and it is routinely obscured.

There are well over a hundred published studies. The great majority are experiments in rats and mice, with a smaller number of in vitro cell culture studies. A substantial proportion of that body of work originates from the laboratory of Predrag Sikirić at the University of Zagreb, which has published on the compound for roughly three decades. That is not in itself a criticism of the work — long-running programmes are normal in pharmacology — but concentration of a literature in one group is a recognised source of concern. Independent replication by unaffiliated laboratories is the mechanism by which science filters out methodological quirks, unconscious bias in model selection, and results that simply do not generalise. For BPC-157, independent replication remains comparatively sparse relative to the volume of publications.

A 2025 systematic review examining orthopaedic and sports medicine applications screened several hundred articles and found that, of the studies meeting inclusion criteria, only one involved human subjects; the remainder were preclinical. That ratio is the honest summary of the field.

Beyond that, the human record consists of case reports, small uncontrolled observational series, and a very small safety pilot. None of these designs can establish whether an effect exists. Case reports cannot separate an intervention from natural recovery, regression to the mean, or placebo response. An uncontrolled series cannot either. A safety pilot with a handful of participants can, at best, indicate that nothing dramatic happened in those particular people — it says nothing about efficacy and has almost no power to detect uncommon harms.

The proposed mechanism

The mechanism most often advanced in the preclinical literature is angiogenesis: the formation of new blood vessels. Cell-culture and animal work has reported that BPC-157 increases expression of vascular endothelial growth factor receptor 2 (VEGFR2), with downstream signalling through Akt and endothelial nitric oxide synthase (eNOS). Separate work published in Scientific Reports in 2020 examined effects on vasomotor tone and implicated a Src–caveolin-1–eNOS pathway, with the observed vasodilation abolished by nitric oxide synthase inhibition — which is the kind of pharmacological control that makes a mechanistic claim more credible than a bare correlation.

Endothelial cell migration and focal adhesion signalling have also been reported as affected in culture. These are plausible, internally coherent findings. What they establish is a mechanism by which the compound could act in the systems studied. They do not establish that it does anything measurable in a human being, and mechanistic plausibility has a long and poor track record as a predictor of clinical effect.

Regulatory status

BPC-157 is not licensed as a medicine anywhere. It holds no marketing authorisation from the MHRA in the United Kingdom, no approval from the FDA in the United States, and none from the EMA. It has not completed the trial programme that such approval would require. It is also not a permitted food supplement ingredient, and regulators in several jurisdictions have issued warnings about its appearance in wellness and anti-ageing products.

In sport, WADA added BPC-157 to the 2022 Prohibited List, naming it explicitly as an example under section S0, Non-Approved Substances — the first time a substance had been named that way in that section. S0 covers pharmacological agents with no current approval by any governmental health authority for human therapeutic use, and it is prohibited at all times, in and out of competition. Because there is no approved therapeutic use, there is no realistic basis for a Therapeutic Use Exemption.

The angiogenesis question cuts both ways

If the proposed mechanism is real, it deserves more scrutiny than it usually gets. Angiogenesis is not a uniformly desirable process. Tumour growth beyond a very small size depends on recruiting a blood supply, and an entire class of oncology drugs works by inhibiting VEGF signalling to starve tumours of vasculature. A compound proposed to do the opposite — to upregulate VEGFR2 signalling systemically — raises an obvious theoretical concern that the existing literature has not addressed with long-term carcinogenicity studies or extended human safety data.

This is not a claim that BPC-157 causes harm. It is a statement that the question has not been answered, and that the absence of an answer is itself a finding. Short rodent studies are structurally incapable of detecting slow processes. The honest position is that the long-term safety profile in humans is unknown, and that a plausible theoretical concern exists which no published study has yet resolved.

What would change the picture

Adequately powered, randomised, blinded, placebo-controlled human trials with pre-registered endpoints, conducted by groups independent of the original research programme, with pharmacokinetic characterisation and follow-up long enough to detect delayed effects. Until that exists, BPC-157 remains an interesting preclinical compound with an unusually large gap between the confidence of its promotion and the strength of its evidence.

Image: “Xray crystal structure PDB-7si9” by Vcpmartin, licensed under CC BY-SA 4.0.